Skip to main content

Virologic Failure clinical trials at UCSF

1 in progress, 0 open to eligible people

Showing trials for
  • Virologic Failure on TLD in Sub-Saharan Africa

    Sorry, not yet accepting patients

    The RESOLVE trial is an open, parallel arm, randomized clinical trial which aims to determine the optimal strategy for management of virologic failure on first-line antiretroviral therapy (ART) with tenofovir, lamivudine, and dolutegravir (TLD) in sub-Saharan Africa. The primary outcome of interest will be viral suppression to <50 copies/mL at 48 weeks using the FDA snapshot definition. The study will be conducted in Uganda and South Africa.

Last updated: